JP2013545448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545448A5 JP2013545448A5 JP2013535100A JP2013535100A JP2013545448A5 JP 2013545448 A5 JP2013545448 A5 JP 2013545448A5 JP 2013535100 A JP2013535100 A JP 2013535100A JP 2013535100 A JP2013535100 A JP 2013535100A JP 2013545448 A5 JP2013545448 A5 JP 2013545448A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide antigen
- antigen
- polypeptide
- composition
- chlamydia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 792
- 102000036639 antigens Human genes 0.000 claims description 792
- 108091007433 antigens Proteins 0.000 claims description 792
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 652
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 651
- 229920001184 polypeptide Polymers 0.000 claims description 650
- 241000606161 Chlamydia Species 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 103
- 239000002671 adjuvant Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 241000606153 Chlamydia trachomatis Species 0.000 claims description 5
- 229940038705 chlamydia trachomatis Drugs 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40516210P | 2010-10-20 | 2010-10-20 | |
| US61/405,162 | 2010-10-20 | ||
| PCT/US2011/057143 WO2012054755A1 (en) | 2010-10-20 | 2011-10-20 | Chlamydia antigens and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032672A Division JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013545448A JP2013545448A (ja) | 2013-12-26 |
| JP2013545448A5 true JP2013545448A5 (esLanguage) | 2014-12-04 |
Family
ID=45975625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535100A Pending JP2013545448A (ja) | 2010-10-20 | 2011-10-20 | クラミジア抗原及びその使用 |
| JP2016032672A Pending JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032672A Pending JP2016106117A (ja) | 2010-10-20 | 2016-02-24 | クラミジア抗原及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120135025A1 (esLanguage) |
| EP (1) | EP2629793A4 (esLanguage) |
| JP (2) | JP2013545448A (esLanguage) |
| AU (2) | AU2011316924A1 (esLanguage) |
| CA (1) | CA2849391A1 (esLanguage) |
| WO (1) | WO2012054755A1 (esLanguage) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597182A (en) | 2009-05-22 | 2014-07-25 | Genocea Biosciences Inc | Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| WO2011112906A2 (en) | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Novel immunogens and methods for discovery and screening thereof |
| JP6055776B2 (ja) | 2010-11-24 | 2016-12-27 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法 |
| WO2013078299A1 (en) * | 2011-11-23 | 2013-05-30 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
| WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| EP3519427A4 (en) | 2016-09-28 | 2020-03-11 | Genocea Biosciences Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES |
| WO2018070067A1 (ja) | 2016-10-14 | 2018-04-19 | パナソニックＩｐマネジメント株式会社 | プロジェクションシステム、プロジェクション方法、飛行体システム及び飛行体 |
| CN112969474A (zh) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | 多价肺炎球菌疫苗 |
| EP4284832A1 (en) * | 2021-01-29 | 2023-12-06 | (INSERM) Institut National de la Santé et de la Recherche Médicale | Chlamydia trachomatis antigenic polypeptides and uses thereof for vaccine purposes |
| US12036276B2 (en) | 2021-09-09 | 2024-07-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041490B1 (en) * | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
| AU1722300A (en) * | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| KR100982204B1 (ko) * | 2001-12-12 | 2010-09-14 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 클라미디아 트라코마티스에 대한 면역화 |
| ATE478091T1 (de) * | 2003-02-24 | 2010-09-15 | Pasteur Institut | Anwendung des cpn104 polypeptids aus chlamydia pneumoniae oder dessen antikörper zur diagnose einer chlamydia infektion |
| MXPA05013260A (es) * | 2003-06-26 | 2006-03-09 | Chiron Corp | Composiciones inmunogenicas para chlamydia trachomatis. |
| WO2006045308A2 (en) * | 2004-10-25 | 2006-05-04 | Statens Serum Institut | Chlamydia trachomatis antigens for vaccine and diagnostic use |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| CA2633142A1 (en) * | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, S.R.L. | Chlamydial antigens |
| WO2010042206A1 (en) * | 2008-10-09 | 2010-04-15 | Board Of Regents, University Of Texas System | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease |
| US20110293664A1 (en) * | 2008-12-17 | 2011-12-01 | Genocea Biosciences, Inc. | Chlamydia antigens and uses thereof |
| EP3549602A1 (en) * | 2009-03-06 | 2019-10-09 | GlaxoSmithKline Biologicals S.A. | Chlamydia antigens |
-
2011
- 2011-10-20 AU AU2011316924A patent/AU2011316924A1/en not_active Abandoned
- 2011-10-20 EP EP11835162.6A patent/EP2629793A4/en not_active Withdrawn
- 2011-10-20 CA CA2849391A patent/CA2849391A1/en not_active Abandoned
- 2011-10-20 US US13/277,996 patent/US20120135025A1/en not_active Abandoned
- 2011-10-20 WO PCT/US2011/057143 patent/WO2012054755A1/en not_active Ceased
- 2011-10-20 JP JP2013535100A patent/JP2013545448A/ja active Pending
-
2016
- 2016-02-24 JP JP2016032672A patent/JP2016106117A/ja active Pending
- 2016-03-24 US US15/080,324 patent/US20170043005A1/en not_active Abandoned
- 2016-04-21 AU AU2016202528A patent/AU2016202528A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545448A5 (esLanguage) | ||
| Lin et al. | Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection | |
| van Riet et al. | Mucosal IgA responses in influenza virus infections; thoughts for vaccine design | |
| JP2016106117A5 (esLanguage) | ||
| Dziadek et al. | Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice | |
| JP2012512257A5 (esLanguage) | ||
| JP2014534202A5 (esLanguage) | ||
| Kovacs-Nolan et al. | The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody-and cell-mediated immune responses in mice | |
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| JP2012501959A5 (esLanguage) | ||
| Li et al. | Co-stimulation with TLR7 agonist imiquimod and inactivated influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production | |
| JP2025085695A (ja) | 既存の微生物免疫を利用した癌処置 | |
| EP2909238A1 (en) | Improved human herpesvirus immunotherapy | |
| TWI507413B (zh) | 脂質化多抗原表位疫苗 | |
| JP2015529677A5 (esLanguage) | ||
| Zhao et al. | Enhanced immune response and protective efficacy of a Treponema pallidum Tp92 DNA vaccine vectored by chitosan nanoparticles and adjuvanted with IL-2 | |
| Alipour et al. | The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice | |
| Maraghi et al. | Evaluation of immunogenicity and protective effect of DNA vaccine encoding surface antigen1 (SAG1) of Toxoplasma gondii and TLR-5 ligand as a genetic adjuvant against acute toxoplasmosis in BALB/c mice | |
| Allahyari et al. | Co-delivery of PLGA nanoparticles loaded with rSAG1 antigen and TLR ligands: An efficient vaccine against chronic toxoplasmosis | |
| Maspi et al. | DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice | |
| Ge et al. | Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70 | |
| Adam et al. | A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity | |
| Pirincal et al. | Amino Terminal Region of Crimean‐Congo Hemorrhagic Fever Virus (CCHFV) Nucleocapsid (NP) Protein Contains Dominant Epitopes Recognised by Cellular Immunity | |
| JP2023526766A (ja) | ヒトサイトメガロウイルスポリエピトープワクチン組成物 | |
| Zhan et al. | Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen |